TWI860334B - 芳香族衍生物、包括其之藥物組合物與試劑盒及其用途 - Google Patents

芳香族衍生物、包括其之藥物組合物與試劑盒及其用途 Download PDF

Info

Publication number
TWI860334B
TWI860334B TW109107205A TW109107205A TWI860334B TW I860334 B TWI860334 B TW I860334B TW 109107205 A TW109107205 A TW 109107205A TW 109107205 A TW109107205 A TW 109107205A TW I860334 B TWI860334 B TW I860334B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
tautomer
stereoisomer
acceptable salt
Prior art date
Application number
TW109107205A
Other languages
English (en)
Chinese (zh)
Other versions
TW202100514A (zh
Inventor
寧 邵
王丁
袁宏斌
弗蘭克 凱澤
Original Assignee
中國商保仕健生物科技（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國商保仕健生物科技（上海）有限公司 filed Critical 中國商保仕健生物科技（上海）有限公司
Publication of TW202100514A publication Critical patent/TW202100514A/zh
Application granted granted Critical
Publication of TWI860334B publication Critical patent/TWI860334B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW109107205A 2019-03-05 2020-03-05 芳香族衍生物、包括其之藥物組合物與試劑盒及其用途 TWI860334B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2019/076926 2019-03-05
PCT/CN2019/076926 WO2020177067A1 (en) 2019-03-05 2019-03-05 Aromatic derivatives, preparation methods, and medical uses thereof
WOPCT/CN2020/075849 2020-02-19
PCT/CN2020/075849 WO2020177534A1 (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Publications (2)

Publication Number Publication Date
TW202100514A TW202100514A (zh) 2021-01-01
TWI860334B true TWI860334B (zh) 2024-11-01

Family

ID=72337401

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109107205A TWI860334B (zh) 2019-03-05 2020-03-05 芳香族衍生物、包括其之藥物組合物與試劑盒及其用途

Country Status (10)

Country Link
US (1) US11976058B2 (https=)
EP (1) EP3935048A4 (https=)
JP (1) JP7470708B2 (https=)
KR (1) KR20210135558A (https=)
CN (1) CN111902400B (https=)
CA (1) CA3132405A1 (https=)
PH (1) PH12021552133A1 (https=)
SG (1) SG11202109522VA (https=)
TW (1) TWI860334B (https=)
WO (2) WO2020177067A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595371B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Contact lens with improved vision break-up time
US12595370B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US20220194944A1 (en) * 2020-12-18 2022-06-23 Johnson & Johnson Vision Care, Inc. Photostable mimics of macular pigment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108992A1 (en) * 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107286130A (zh) * 2016-04-13 2017-10-24 成都融科博海科技有限公司 一种激酶选择性抑制剂
CN104540809B (zh) * 2012-07-11 2018-12-11 蓝印药品公司 成纤维细胞生长因子受体的抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6043347B2 (ja) 2011-06-16 2016-12-14 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 線維芽細胞増殖因子受容体４の発現のアンチセンス調節
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PH12016500676B1 (en) 2013-10-18 2022-07-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
TN2016000115A1 (en) 2013-10-25 2017-07-05 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
US10125090B2 (en) 2014-06-24 2018-11-13 Covestro Deutschland Ag Process for preparation of di- and polyamines of the diphenylmethane series
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US9580423B2 (en) * 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105906630B (zh) 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
AU2017378943B2 (en) * 2016-12-19 2020-06-18 Abbisko Therapeutics Co., Ltd. FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
CA3074885A1 (en) * 2017-09-05 2019-03-14 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
CN109224235B (zh) 2018-10-23 2020-05-19 孙喜家 一种双腔管
CN109331654A (zh) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 一种有机废气光催化氧化装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540809B (zh) * 2012-07-11 2018-12-11 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
WO2015108992A1 (en) * 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107286130A (zh) * 2016-04-13 2017-10-24 成都融科博海科技有限公司 一种激酶选择性抑制剂

Also Published As

Publication number Publication date
CN111902400A (zh) 2020-11-06
EP3935048A4 (en) 2022-11-09
CA3132405A1 (en) 2020-09-10
PH12021552133A1 (en) 2022-08-22
JP2022522890A (ja) 2022-04-20
JP7470708B2 (ja) 2024-04-18
US11976058B2 (en) 2024-05-07
WO2020177534A1 (en) 2020-09-10
US20220169634A1 (en) 2022-06-02
EP3935048A1 (en) 2022-01-12
WO2020177067A1 (en) 2020-09-10
TW202100514A (zh) 2021-01-01
SG11202109522VA (en) 2021-09-29
KR20210135558A (ko) 2021-11-15
CN111902400B (zh) 2024-08-30

Similar Documents

Publication Publication Date Title
AU2020256431B2 (en) Bicyclic heterocycles as fgfr4 inhibitors
US12227517B2 (en) Pyridazinyl-thiazolecarboxamide compound
US20250057852A1 (en) Bicyclic heterocycles as fgfr inhibitors
KR101961500B1 (ko) 세린/트레오닌 키나제 억제제
US9840503B2 (en) Heterocyclic compounds and uses thereof
CN111801331A (zh) 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
US11691971B2 (en) Naphthyridinone compounds as JAK2 V617F inhibitors
US12428420B2 (en) Tricyclic heterocycles as FGFR inhibitors
TWI860334B (zh) 芳香族衍生物、包括其之藥物組合物與試劑盒及其用途
US10723705B2 (en) Heterocyclic compounds and uses thereof
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
US20240190876A1 (en) Tricyclic Urea Compounds As JAK2 V617F Inhibitors
US20240083898A1 (en) Tricyclic triazolo compounds as dgk inhibitors
CN118946566A (zh) 作为泛素特异性蛋白酶7抑制剂的杂环化合物
TW202241904A (zh) 三環類化合物及其用途
WO2020198067A1 (en) Pkm2 modulators and methods for their use
HK40040054B (zh) 芳香族衍生物其制备方法和医学用途
HK40040054A (en) Aromatic derivatives, preparation methods, and medical uses thereof
HK40097521A (zh) 三环类化合物及其用途
US20250163059A1 (en) Heterocyclic kinase inhibitors
US20260049093A1 (en) Bicyclic Ureas As Kinase Inhibitors
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
HK40130202A (zh) 杂芳基杂环化合物及其用途
HK1227022B (zh) 絲氨酸/蘇氨酸激酶抑制劑